GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
LA JOLLA, CA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced it has entered into a collaboration with the UK consortia, National Institute for Health and Care Research Respiratory Translational Research Collaboration (“NIHR Respiratory TRC”) to advance its leading NKT regulation technology to treat inflammatory, fibrotic and autoimmune diseases.
- Together with the NIHR Respiratory TRC, GRI Bio will design and execute complex multi-center studies that accelerate research for the benefit of respiratory disease patients.
- “As a Company, we are dedicated to revolutionizing the way that inflammatory, fibrotic and autoimmune diseases like IPF are treated.
- The establishment of this collaboration represents another important step forward as we work to advance our clinical development programs.
- The NIHR Respiratory TRC offers cutting-edge translational research that we believe will assist in executing clinical studies underpinned by excellent scientific rigor.